01931nas a2200313   4500000000100000008004100001260001300042653000900055653001500064653003000079653001100109653001100120653001000131653002300141653001200164653000900176653001600185653003900201653001500240653003000255100001300285700001400298700001300312245011300325300001100438490000700449520114700456022001401603       1998                            d  c1998 Jul10aAged10aBangladesh10aDrug Therapy, Combination10aFemale10aHumans10aJapan10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aPeripheral Nervous System Diseases10aRecurrence10aWorld Health Organization1 aHatano K1 aMatsuki T1 aMakino M00a[The trend of leprosy treatment in which the prevention of peripheral nerve damage being as its main theme].  a353-600 v673 a<p>We have examined in leprosy in Bangladesh the change in the rate of peripheral nerve damage before and after the treatment. In the well-organized NGO program where the early diagnose is given, the damage rate improves slightly during the treatment. But among the MB cases, it has been found that the damage rate taken at the time of patient's first check-up still stays high. Furthermore, during the treatment of MB cases, 72% cases show the episode of neuritis, and even during two years of observation period after treatment, 15% cases show the same episode. Among the recurrent cases of last ten years in Oku-Komyo-en, we have looked into the ways of drugs prescribed for the treatment of previous recurrent term in the double recurrent cases. In these prescription, the amount of each dosage was relatively a little and the prescription period was rather long. In RFP, prescription frequency was relatively high, and in DDS and CLF, they were low. We think that the treatment of leprosy in Japan should be based on WHO's regimen. However before making Japanese regimen, it is necessary to discuss more when to finish the treatment.</p>  a1342-3681